|
gptkbp:instance_of
|
gptkb:drug
|
|
gptkbp:activities
|
neuraminidase inhibitor
|
|
gptkbp:appointed_by
|
inhalation
|
|
gptkbp:approves
|
gptkb:FDA
|
|
gptkbp:availability
|
prescription only
|
|
gptkbp:brand
|
gptkb:Relenza
|
|
gptkbp:class
|
neuraminidase inhibitors
|
|
gptkbp:clinical_trial
|
Phase III
prophylaxis of influenza
|
|
gptkbp:composed_of
|
gptkb:chemical_compound
|
|
gptkbp:contraindication
|
gptkb:asthma
COPD
hypersensitivity to zanamivir
|
|
gptkbp:developed_by
|
gptkb:Glaxo_Smith_Kline
|
|
gptkbp:dosage_form
|
inhalation powder
|
|
gptkbp:duration
|
5 days
|
|
gptkbp:effective_date
|
gptkb:1999
|
|
gptkbp:formulation
|
powder for inhalation
|
|
https://www.w3.org/2000/01/rdf-schema#label
|
Zanamivir
|
|
gptkbp:indication
|
acute influenza
|
|
gptkbp:ingredients
|
C12 H17 N5 O7
|
|
gptkbp:interacts_with
|
other antiviral drugs
probenecid
|
|
gptkbp:invention
|
patented
|
|
gptkbp:is_atype_of
|
J05 A H01
|
|
gptkbp:is_used_for
|
treatment of influenza
|
|
gptkbp:lifespan
|
2.5 to 5 hours
|
|
gptkbp:manager
|
inhalation
|
|
gptkbp:marketed_as
|
multiple countries
|
|
gptkbp:name
|
Essential Medicines
|
|
gptkbp:pharmacokinetics
|
inhibits viral replication
rapid absorption
|
|
gptkbp:population
|
adults and children over 7 years
|
|
gptkbp:provides_information_on
|
CDC recommendations
|
|
gptkbp:research_areas
|
antiviral therapy
|
|
gptkbp:rounds
|
urine
|
|
gptkbp:safety_features
|
Category C
|
|
gptkbp:side_effect
|
headache
nausea
allergic reactions
cough
bronchospasm
throat irritation
|
|
gptkbp:storage
|
room temperature
|
|
gptkbp:targets
|
gptkb:virus
|
|
gptkbp:treatment
|
reduces duration of symptoms
|
|
gptkbp:type_of
|
139110-80-8
|
|
gptkbp:weight
|
315.29 g/mol
|
|
gptkbp:year_created
|
1990s
|
|
gptkbp:bfsParent
|
gptkb:Influenza_B_virus
|
|
gptkbp:bfsLayer
|
6
|